PERTINENT FINDINGS: An AE capture–based theranostic agent, [134Ce]Ce-PSMA-617, demonstrated high tumor specificity, minimal off-target effects, and significant tumor growth inhibition, leading to prolonged survival in preclinical prostate cancer models. Here, FOLH1 is linked to prostate cancer.